CIPLA LTD vs DR. REDDY S LABORATORIES
A side-by-side comparison of CIPLA LTD (CIPLA) and DR. REDDY S LABORATORIES (DRREDDY) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
CIPLA LTD vs DR. REDDY S LABORATORIES are evenly matched on the numbers (7–7). The breakdown below shows where each one wins.
- Valuation13
- Profitability31
- Growth11
- Size & financial health22
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
DRREDDY takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
CIPLA takes 3/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
EvenThree-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
EvenScale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
- − ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.24%"]
- + ["Company's working capital requirements have reduced from 85.1 days to 67.8 days"]
- − ["Dividend payout has been low at 13.2% of profits over last 3 years"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.